BioAge Labs (BIOA) stock price, chart and financials
Price chart
Financials
- Revenue (quarter)
- $2.5M
- Gross margin
- 100.00%
- Net income (quarter)
- −$26.1M
- Net margin
- −912.25%
- Return on equity
- −28.21%
- Book value per share
- $8.19
- Price to book
- 0.66
- Debt to assets
- 5.55%
Company profile
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
Frequently asked questions
Is BioAge Labs (BIOA) profitable?
No. BioAge Labs reported a net loss of $94.5M over the trailing twelve months.
How much revenue does BioAge Labs (BIOA) make?
BioAge Labs generated $10.4M in revenue over the trailing twelve months, up 1.62% year over year.
How do I buy stock in BioAge Labs (BIOA)?
BIOA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.